Cellectis S.A. has released its financial results for the third quarter of 2026, marking a pivotal moment as the company transitions its focus towards in vivo gene editing. This update is significant as it not only reflects Cellectis's current financial health but also outlines its strategic direction in the competitive field of biological products.

On November 12, 2026, Cellectis reported its financial results for the quarter ending September 30, 2026, alongside updates on its gene editing pipeline. The company is emphasizing its commitment to developing genetic medicines aimed at diseases that require long-term treatment. Cellectis's CEO, André Choulika, expressed confidence in the advancements made, particularly with the .HEAL-101 program, which has shown up to 70% editing efficiency of the APOC3 gene in preclinical models.

Background

Cellectis S.A. is a genome engineering company based in Paris, France, specializing in biological products, specifically those that do not involve diagnostic substances (SIC 2836). The company trades on the Nasdaq under the ticker symbol CLLS. Recent filings indicate a shift in strategy aimed at enhancing its gene editing capabilities, which could have significant implications for its market position.

What the Filing Says

The recent filing outlines several key developments. Cellectis reported, “.HEAL-101 achieved up to 70% in vivo APOC3 editing with liver-restricted activity and confirmed 76% triglyceride reduction in murine models.” Additionally, the company noted that the Phase 1 investigator-initiated trial in China for .HEAL-101 is on track, with preliminary clinical data expected in the second half of 2027.

Furthermore, .HEAL-201 has demonstrated over 90% reduction in plasma PCSK9 in humanized liver mouse models, with preliminary clinical data anticipated in the first half of 2028. As of September 30, 2026, Cellectis reported cash and cash equivalents totaling $149 million, aiming to extend its cash runway into the second half of 2028.

Impact

This strategic pivot towards in vivo gene editing may significantly impact various stakeholders, including patients, healthcare providers, and investors. The advancements in Cellectis's pipeline could lead to new treatment options for conditions requiring genetic intervention, potentially altering the treatment landscape for chronic diseases.

What's Next

Cellectis plans to continue its strategic transformation, which includes a substantial reduction in workforce, with an anticipated decrease of up to 70% in global headcount. This restructuring is part of a broader realignment to focus on its gene editing initiatives. The filing does not specify the timeline for further developments beyond the anticipated clinical data releases.